Objectives: To investigate the prognostic significance of DNA ploidy and silver-stained nucleolar organizer regions (AgNOR), their relation to the cytological grades of cervical dysplasia and correlation of cells in the S-phase of the cell cycle and DNA ploidy with AgNOR count. Methods: Multiparametric DNA flow-cytometric analysis and AgNOR count were performed on cervical smear samples, cytologically diagnosed as normal (n = 196), atypical squamous cells of unknown significance (ASCUS, n = 98) and various grades of cervical dysplasia (n = 127). Results: Among the cytological grade, aneuploid cases from low-grade squamous intraepithelial lesion (mild) and high-grade squamous intraepithelial lesion (moderate and severe) groups were showing high AgNOR counts (ranges 4.33–5.86 and 5.91–7.42, respectively). Aneuploid cases from the ASCUS group also presented high AgNOR (range 3.72–4.93). The high percentage of cells in the S-phase (>12%) correlated with these 2 parameters in the ASCUS and dysplasia groups. After grouping the cases into those with high (>4.0) and low (<4.0) AgNOR counts, significant correlations in the group with high AgNOR count with DNA ploidy, S-phase and cytological grade were recorded (p < 0.001). Results obtained from follow-up study revealed that cases with aneuploidy, high AgNOR count and S-phase fraction presented with a progressive trend of disease. Conclusions: Thus, the study shows that high AgNOR count, S-phase fraction and aneuploid DNA have prognostic significance in the early detection of cervical cancer.

1.
Tiffen J, Mahon SM: Cervical cancer: what should we tell women about screening? Clin J Oncol Nurs 2006;10:527–531.
2.
Hopman AH, Theelen W, Hommelberg PP, Kamps MA, Herrington CS, Morrison LE, Speel EJ, Smedts F, Ramaekers FC: Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer. J Pathol 2006;210:412–419.
3.
Lin ZH, Liu MZ, Zhao YW, Wu QY, Liu SP, Kim I: Study of p16(INK4A) expression and DNA ploidy in HPV-negative cervical cancers and precursors. Zhonghua Bing Li Xue Za Zhi 2006;35:412–416.
4.
Bollmann R, Mehes G, Speich N, Schmitt C, Bollmann M: Aberrant, highly hyperdiploid cells in human papillomavirus-positive; abnormal cytologic samples are associated with progressive lesions of the uterine cervix. Cancer 2005;105:96–100.
5.
Gasinska A, Urbanski K, Gruchala A, Biesaga B, Kojs Z: A ratio of apoptosis to mitosis, proliferation pattern and prediction of radiotherapy response in cervical carcinoma. Neoplasma 2002;49:379–386.
6.
Kashyap V, Das BC: DNA aneuploidy and infection of human papillomavirus type 16 in preneoplastic lesions of the uterine cervix: correlation with progression to malignancy. Cancer Lett 1998;123:47–52.
7.
Bollmann R, Mehes G, Torka R, Speich N, Schmitt C, Bollmann M: Human papillomavirus typing and DNA ploidy determination of squamous intraepithelial lesions in liquid-based cytologic samples. Cancer 2003;99:57–62.
8.
Lorenzato M, Caudroy S, Bronner C, Evrard G, Simon M, Durlach A, Birembaut P, Clavel C: Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions? Hum Pathol 2005;36:1101–1107.
9.
Melsheimer P, Klaes R, von Knebel Doeberitz M, Bastert G: Prospective clinical study comparing DNA flow cytometry and HPV typing as predictive tests for persistence and progression of CIN I/II. Cytometry2001;46:166–171.
10.
Rocher AE, Gonzalez A, Palaoro LA, Blanco AM: Usefulness of AgNOR technique and CEA expression in atypical metaplastic cells from cervical smears. Anal Quant Cytol Histol 2006;28:130–136.
11.
Pahuja S, Choudhury M, Gupta U: AgNOR counts in exfoliative cytology smears of preinvasive and invasive squamous epithelial lesions of cervix. J Cytology 2003;20:177–179.
12.
Chung T, Cheung TH, Wong FS, Wong UF: Ki-67 and AgNOR staining in squamous cell carcinoma of the cervix: a comparison. Gynecol Obstet Invest 1994;37:127–129.
13.
Ploton D, Menager M, Jeannesson P, Himber G, Pigeon F, Adnet JJ: Improvement in the staining and the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level. Histocheml J 1986;18:5–14.
14.
Morton CC, Brown JA, Holmes WM, Nance WE, Wolf B: Stain intensity of human nucleolus organizer region reflects incorporation of uridine into mature ribosomal RNA. Exp Cell Res 1983;1415:405–413.
15.
Hubbell HR: Silver staining as an indicator of active ribosomal genes. Stain Technol 1985;60:285–294.
16.
Sirri V, Roussel P, Hernandez-Verdun D: The AgNOR proteins: qualitative and quantitative changes during the cell cycle. Micron 2000;31:121–126.
17.
Derenzini M, Trere D: AgNOR proteins as a parameter of the rapidity of cell proliferation. Zentralbl Pathol 1994;140:7–10.
18.
Tosi P, Cintorino M, Santopietro R, Lio R, Barbini P, Ji H, Chang F, Kataja V, Syrjanen S, Syrjanen K: Prognostic factors in invasive cervical carcinomas associated with human papillomavirus (HPV): quantitative data and cytokeratin expression. Pathol Res Pract 1992;188:866–873.
19.
Trere D, Ceccarelli C, Danova M, Derenzini M: In vivo bromodeoxyuridine labelling index, AgNOR protein expression and DNA content in human tumours. Eur J Histochem 1996;40:17–26.
20.
Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey Raab S, Sherman M, Wilbur D, Wright T Jr, Young N; Forum Group Members; Bethesda 2001 Workshop: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114–2119.
21.
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139 271–279.
22.
Rabinovitch PS: DNA content histogram and cell cycle analysis. Methods Cell Biol 1994;41:263–296.
23.
Baisch H, Gohde W, Linden WA: Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Radiat Environ Biophys 1975;12:31–39.
24.
Salud A, Porcel JM, Rajkundalia B, Camplejohn RS, Taub NA: Prognostic significance of DNA ploidy, S-phase fraction, and P-glycoprotein expression in colorectal cancer. J Surg Oncol 1999;72:167–174.
25.
Smith PJ, Skilbeck N, Harrison A, Crocker J: The effect of a series of fixatives on the AgNOR technique. J Pathol 1988;155:109–112.
26.
Crocker J, Boldy DR, Egan MJ: How should we count AgNORs? Proposals for a standardized approach. J Pathol 1989;158:185–188.
27.
Hopman AH, Kamps MA, Smedts F, Speel EJ, Herrington CS, Ramaekers FC: HPV in situ hybridization: impact of different protocols on the detection of integrated HPV. Int J Cancer 2005;115:419–428.
28.
Reich O, Purstner P, Klaritsch P, Haas J, Lahousen M, Tamussino K, Winter R: Prognostic significance of preoperative DNA flow cytometry in surgically-treated cervical cancer. Eur J Gynaecol Oncol 2003;24:13–17.
29.
Mourad WA, Erkman-Balis B, Livingston S, Shoukri M, Cox CE, Nicosia SV, Rowlands DT Jr: Argyrophilic nucleolar organizer regions in breast carcinoma: correlation with DNA flow cytometry, histopathology, and lymph node status. Cancer 1992;69:1739–1744.
30.
Huang MS, Tsai MS, Hwang JJ, Wang TH: Comparison of nucleolar organiser regions and DNA flow cytometry in the evaluation of pleural effusion. Thorax 1994;49:1152–1156.
31.
Thickett KM, Griffin NR, Griffiths AP, Wells M: A study of nucleolar organizer regions in cervical intraepithelial neoplasia and human papillomavirus infection. Int J Gynecol Pathol 1989;8:331–339.
32.
Terlikowski S, Dzieciol J, Mazurek A, Sulkowski S, Boron R, Oniszczuk M, Lejmanowicz K: A morphometric study of nucleolar organiser regions in cervical intraepithelial neoplasia. Folia Morphol (Warsz) 2004:63:209–212.
33.
Dey P, Das R, Sabuddin: Correlations between apoptotic and proliferative indices in cervical intraepithelial neoplasia and carcinoma. Indian J Pathol Microbiol 2000;43:271–275.
34.
Sakai YI, Sakai AT, Isotani S, Cavaliere MJ, de Almeida LV, Calore EE: Morphometric evaluation of nucleolar organizer regions in cervical intraepithelial neoplasia. Pathol Res Pract 2001;197:189–192.
35.
Misra JS, Das V, Srivastava AN, Singh U, Singh M: AgNOR counts in cervical smears under normal and other cytopathologic conditions. Anal Quant Cytol Histol 2005;27:337–340.
36.
Johnson TS, Adelson MD, Sneige N, Williamson KD, Lee AM, Katz R: Cervical carcinoma DNA content, S-fraction, and malignancy grading. I. Interrelationships. Gynecol Oncol 1987;26:41–56.
37.
Lumachi F, Ermani M, Marino F, Poletti A, Basso SM, Iacobone M, Favia G: Relationship of AgNOR counts and nuclear DNA content to survival in patients with parathyroid carcinoma. Endocr Relat Cancer 2004;11:563–569.
38.
Sah SP, Dawar R, Kumar L, Gupta SD: Nucleolar organizer regions as a prognostic indicator in epithelial cancers of the ovary. Int J Gynecol Pathol 2004;23:347–353.
39.
Wilailak S, Rochanawutanon M, Srisupundit S, Aumkhyan A, Pattanapanyasat K: Flow cytometric analysis of DNA ploidy and S-phase fraction of stage IIIB cervical carcinoma. Eur J Gynaecol Oncol 2004;25:428–430.
40.
Moureau-Zabotto L, Bouchet C, Cesari D, Uzan S, Lefranc JP, Antoine M, Genestie C, Deniaud-Alexandre E, Bernaudin JF, Touboul E, Fleury-Feith J: Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: review of a series of 271 patients with stage I and II breast cancer. Cancer Radiother 2005;9:575–586.
41.
Horn LC, Raptis G, Nenning H: DNA cytometric analysis of surgically treated squamous cell cancer of the uterine cervix, stage pT1b1-pT2b. Anal Quant Cytol Histol 2002;24:23–29.
42.
Gasinska A, Krzyszkowski T, Niemiec J, Adamczyk A, Skolyszewski J: Prognostic significance of DNA ploidy and proliferation rate in human astrocytic gliomas. Folia Histochem Cytobiol 2000;38:175–180.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.